The Board of Directors
Garth Cumberlidge, PhD, Chairman of the Board
Dr Cumberlidge is currently President and CEO of Mimetogen Pharmaceuticals Inc., a biotechnology company developing novel neuroprotective and neurostimulatory compounds for the treatment of ocular diseases. Prior to Mimetogen, Dr. Cumberlidge served as President & CEO of Qbiogene Inc., a company providing life sciences research products and custom cGMP manufacturing services to academic, biotechnology and pharmaceutical researchers worldwide
Dr. Cumberlidge holds degrees in Biochemistry and Genetics from the University of London (U.K.) and in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin (Germany).
Patricia Zilliox, PH.D.
Dr. Zilliox is currently the Chief Drug Development Officer of the Clinical Research Institute, a division of the Foundation Fighting Blindness.
Dr. Zilliox was previously Head of Clinical Development at Alcon Laboratories, where she had global accountability for planning, development, execuof clinical trials in ophthalmology across Europe for Alcon as well.
Dr. Zilliox received a Pharmacy degree and a PhD from the University Louis Pasteur in Strasbourg France. She also serves as President of the French-American Chamber of Commerce (FACC) in Dallas.
Frank Kalkbrenner, MD, PhD.$
Dr. Kalkbrenner is the Managing Director of the Boehringer Ingelheim Corporate Venture Fund.
In 1997, Dr. Kalkbrenner joined Schering AG as senior scientist in Experimental Dermatology. He joined Boehringer Ingelheim in 1999 and held several positions in the department of Pulmonary Research. In 2005 he took over the responsibility for the Licensing Department, and led the licensing activities of the Corporate Boehringer Ingelheim organization. In addition, he built up the NBE Research unit at the German Research site in Biberach.
Dr. Kalkbrenner also serves as board member of STAT Diagnostica in
Barcelona, of Acousia Therapeutics in Tübingen. He is also a member of
the supervisory and the advisory board of Inserm Transfer Initiative a
French Seed Investment Fund based in Paris.
Ms Chahra Louafi
Mrs Louafi the Investment Director and head of the fund for biotherapies and rare diseases at BpiFrance which she joined in 2001. She is also Vice-president of the Supervisory Board of Inserm Transfert Initiative and member of the Supervisory Board of Cap Décisif Management. Previously, she was in charge of project development and company inceptions in a private incubator for biotechnology companies. She sits on several boards, notably DBV Technologies, Sensorion, Eyevensys, MedDay, Pixium Vision and Lysogene.
Ms Catherine Boule
Mrs Boule is a Partner at CapDecisif, a Paris-based Seed Fund, which she joined in 2003. She is a board Director at Axess Vision Technology, EyeBrain, Innavirvax, Eviagenics, Physikron, VitamFero, Watchfrog, Eyevensys and Voluntis.
Ohad Hammer, PhD.
Ohad has been a biotech analyst at Pontifax for 8 years. He is involved in identifying as well as evaluating new investment opportunities. Ohad focuses on early-stage projects and oversees scouting, due diligence and company formation. He also supports development and business development activities within Pontifax’s early-stage portfolio companies. Ohad obtained his M.S. in Biology from Tel-Aviv University and writes about small and mid-cap biotech stocks on his blog: www.orf-blog.com
Dr. Francine Behar-Cohen, Founder and CHief Scientific Officer of Eyevensys, MD, PHP
Professor Francine Behar-Cohen is since 2013 the Chief Medical
Officer of the Gonin Lausanne Ophthalmology Hospital in Switzerland. She
was previously Professor of Ophthalmology at Paris Descartes University
(France), Head of the Department of Ophthalmology of Hötel-Dieu -
University of Paris Descartes Hospital, and Director of of the
"Physiopathology of Ocular Diseases lab at the Cordeliers INSERM Centre
(UMRS 872). She has authored over 164 publications since 1999. Very
entrepreneurially oriented, Professor Behar-Cohen founded Eyegate Pharma
in 1997 (OPTIS Pharma), and Eyevensys in 2008.